LTT Bio-Pharma Announces Results of Research on Porous Hydroxyapatite Particles.Tokyo, Japan, May 23, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - On May 22, LTT LTT Lews Therin Telamon (Wheel of Time series) LTT Long-Term Training LTT Light Tactical Trailer LTT Lunar Transit Telescope LTT Limited Team Training LTT Live Training Transformation Bio-Pharma announced the results of its latest research on porous hydroxyapatite hydroxyapatite /hy·droxy·ap·a·tite/ (-ap´ah-tit) an inorganic calcium-containing constituent of bone matrix and teeth, imparting rigidity to these structures. particles. Since February 2005, the company has conducted the research in collaboration with GaleniSearch Laboratories. The two companies confirmed that the preparation of interferon interferon (ĭn'tərfēr`ŏn), any of a group of proteins produced by cells in the body in response to an attack by a virus. A cell infected by a virus releases minute amounts of interferons, which attach themselves to neighboring cells, alpha-2b using porous hydroxyapatite particles helps maintain the proper concentration level in the blood longer than PEG interferon. Further details of the research will be announced later. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion